The Centre for Blood Transplant and Cell Therapies (CBTCT) brings together the largest allogeneic stem cell transplant units in Australia with a focus on identifying transplant and cell therapy strategies to reduce graft versus host disease and improve patient and disease outcomes after transplant. In this webinar series, speakers will review major topics in stem cell transplantation and cell therapy, highlighting how key advances are addressing the current challenges in stem cell transplantation. This webinar features Professor Thomas Luft who is a consultant haematology and oncologist and the taskforce leader for allogeneic haematopoietic stem cell transplant and myelodysplastic syndromes at the Heidelberg University Hospital. Following the completion of his PhD studies at the University of Melbourne, Prof Luft completed post-doctoral fellowships at the Ludwig Institute for Cancer Research in Melbourne as well as the German Cancer Research Centre, where is now the Head of the “Adaptive Immune Regulation” research group. Prof Luft’s research has focused on endothelial complications following allogeneic haematopoietic stem cell transplantation leading to several publications in high impact factor journals and several presentations at international conferences. In this webinar, Prof Luft will be speaking on the early endothelial complications after haematopoeitic stem cell transplant.
Professor Thomas Luft – University of Heidelberg, Heidelberg University Hospital
When: Monday 21 November 2022, 5pm AEDT
For more information click here
Link to webinar:
Link to CBTCT website for all webinar recordings:
The Haematology Society of Australia and New Zealand (HSANZ) and Maddie Riewoldt’s Vision (Maddie’s Vision) are pleased to announce their partnership and commitment to awarding a doctoral scholarship to an Australian or New Zealand applicant demonstrating outstanding merit in both acquired and inherited bone marrow failure syndromes and related disorders.
Maddie’s Vision PhD Research Priorities
This year, Maddie’s Vision and HSANZ will award a PhD scholarship to a successful applicant, whose work contributes to innovative scientific research towards finding new treatments and ultimately cures for both acquired and inherited bone marrow failure syndromes, and aligns with the research priorities of the Maddie’s Vision 5 Pillars of Research:
· Comprehensive clinical data and sample collection on current and newly diagnosed patients with BMF· Genomic and epigenomic control of HSC survival, growth and differentiation
· The components and control of the HSC niche
· Abnormalities of immune function
· Monitoring and predictors of prognosis, response to treatment and disease evolution
Maddie’s Vision and HSANZ PhD Scholarship will:· Provide total funding of no more than $130,000 comprising:
· a. a stipend of $40,333 per annum.
· b. a consumable budget of up to $3,000 per annum.
· Fund each PhD Scholarship for no more than three years of full-time study.
· Be dependent on submission of the required annual report to HSANZ and Maddie’s Vision.
Eligibility1. Citizens or permanent residents of either Australia or New Zealand
2. Able to start the PhD in 2023
3. Willing to present their work as an abstract or oral presentation at the annual Scientific Meeting Blood or HSANZ meeting on at least one occasion throughout their Scholarship
4. Willing to participate in publicity and promotional activity organised by Maddie’s Vision5. Be a member of the Haematology Society of Australia and New Zealand www.hsanz.org.au6. Applicants may only receive one PhD scholarship or Clinical Fellowship from the HSANZ during their lifetime
7. Maddie’s Vision HSANZ PhD Scholarship is not to be held in conjunction with another Scholarship, with the exception of tuition fee exemption. If the applicant accepts another PhD scholarship to run concurrently with the Maddie’s Vision HSANZ PhD scholarship, then the Maddie’s Vision HSANZ PhD scholarship will be discontinued.
Applications must contain a:· Research Proposal (5 pages maximum including references)
· CV of the applicant (3 pages maximum)
· Statement of how the proposed research project directly relates to Maddie’s Vision’s research priorities, and the aims and objectives of the Haematology Society of Australia and New Zealand (1 page maximum)
· Written reference from a referee familiar with the applicant’s recent work history (1 page maximum)
· Research supervisor report to confirm laboratory support for the research proposal. The report should also comment on the suitability of the applicant for the proposed project and likelihood for successful completion of the project within the proposed time period
Application Procedure1. Applications must be accompanied by all relevant documentation
2. Applications must be submitted in full by midnight AEST on the closing date3. Applicants will submit one electronic (pdf) copy of their scholarship application emailed to HSANZ Office
4. Incomplete or late applications will not be considered
5. Applications will be subject to review by a committee comprised of the HSANZ Council and a representative of Maddie’s Vision. The committee’s decision is final
6. The outcome of applications will be announced mid-August 2022
7. Maddie’s Vision and HSANZ reserve the right to not award a scholarship
Download and share flyer - Final HSANZ Maddie's Vision PhD Scholarship Criteria 2022.pdf
Kindly use this coversheet with your application: MRV HSANZ PhD scholarship application coversheet.pdf
Applications Close: Sunday 6 November 2022 at 11:59 pm AEST
Submitting Electronic (pdf) Applications
Electronic applications, along with all supporting documents should be submitted as a single pdf. The pdf should be named MVHSANZ_PhD2022_[FamilyName] and submitted by email, to HSANZ at email@example.com and Maddie’s Vision at firstname.lastname@example.org
Postdoc Research Associate Cancer Immunotherapy, 0094825
Full time Fixed term until July 2023
Three positions available for Research Associates to provide their research expertise in CAR T-Cells
Base Salary $79,784 - $107,516 + 17% superannuation
About the opportunity
The University of Sydney recently appointed Professor Cameron Turtle as the CLEARbridge Chair of Cancer Immunotherapy. Professor Turtle has recently returned to Australia from Seattle where he led clinical and laboratory research teams conducting multiple investigator-initiated phase 1 clinical trials of genetically modified cellular (CAR-T cell) immunotherapies for patients with haematologic malignancies.
The School of Medical Sciences in the Faculty of Medicine and Health has an exciting opportunity for 3 early career researchers to join a newly formed research team supporting the continuation of Professor Turtle’s work in Australia. The Research Associates will be running experiments with the aim of understanding the characteristics of distinct human T-Cell subsets, the development of novel tumor immunotherapies and factors governing the immune response to cancer.
Your key responsibilities will be to:
· carry out relevant lab based research
· supervise and mentor research support staff and students
· assist with various research support requirements
· collaborate with research teams to prepare research findings for publication.
Closing date for applications 11.59pm, 12 October 2022
Please click here to apply Postdoctoral Research Associate Cancer Immunotherapy 0094825
For more information click here
NHMRC Centre for Blood Transplant and Cell Therapies Webinar 17 October 2022
The Centre for Blood Transplant and Cell Therapies (CBTCT) brings together the largest allogeneic stem cell transplant units in Australia with a focus on identifying transplant and cell therapy strategies to reduce graft versus host disease and improve patient and disease outcomes after transplant. In this webinar series, speakers will review major topics in stem cell transplantation and cell therapy, highlighting how key advances are addressing the current challenges in stem cell transplantation. This webinar features Professor Catherine Bollard, who is the current Program Director for Cell Enhancement and Technologies for Immunotherapies at the Children’s National Hospital, Associate Centre Director for Translational Research and Innovation at the GW Cancer Centre and Professor of Pediatrics and Microbiology, Immunology and Tropical Medicine at the George Washington University. Her bench and translational research has focused on improving post-transplant outcomes through developing novel cellular therapeutics, leading to over 200 peer reviewed publications and ongoing independent NIH funding for over a decade. In this webinar, Professor Bollard will be outlining the role of T cell therapies for lymphoma.
Professor Catherine Bollard – Children’s National Hospital, George Washington University
When: Friday 17 October 2022, 8am AEDT
Link to CBTCT website for all webinar recordings:
NHMRC Centre for Blood Transplant and Cell Therapies Webinar 4 October 2022
When: Friday 4 October 2022, 5pm AEDT
Link to webinar:
For more information click here
September is Blood Cancer Month 2022
September is Blood Cancer Month, a time to acknowledge the 135,000 Australians living with blood cancer (including leukaemia, lymphoma, and myeloma), and the further 53 people diagnosed every day. #ThisIsBloodCancer
If you or someone you know is impacted by blood cancer, you/they are not alone. Support is available.
Contact Australia’s Blood Cancer Support line on 1800 620 420 or visit bloodcancer.org.au
Anyone impacted by any type of blood cancer can call 1800 620 420 or visit bloodcancer.org.au to connect with a highly-skilled blood cancer support professional, giving them access to the latest information, personalised supportive care services, and an opportunity to connect with a wider blood cancer community, at no cost.
TGA are seeking applications from professionals with expertise in relevant medical or scientific fields or consumer health issues to support our function as a best practice regulator. Committee members contribute significantly towards the TGA’s regulatory functions by providing independent expert advice relating to the regulation of medicines, devices, vaccines and other products and substances. The statutory advisory committees are:
Committee members do not have full-time duties - some committees meet monthly, with others meeting up to three times a year. Members are remunerated in accordance with the principles and rates set by the Remuneration Tribunal (Remuneration and Allowances for Holders of Part-time Public Office) Determination.
Further information regarding the statutory advisory committees, along with the requirements for applying can be found on our website.
Further enquiries can be made by email to email@example.com.
For information click here
NHMRC Centre for Blood Transplant and Cell Therapies Webinar 26 August 2022
The Centre for Blood Transplant and Cell Therapies (CBTCT) brings together the largest allogeneic stem cell transplant units in Australia with a focus on identifying transplant and cell therapy strategies to reduce graft versus host disease and improve patient and disease outcomes after transplant. In this webinar series, speakers will review major topics in stem cell transplantation and cell therapy, highlighting how key advances are addressing the current challenges in stem cell transplantation. This webinar features Professor Katy Rezvani who is the Sally Cooper Murray Chair in Cancer Research, Professor of Medicine, Chief of Section for Cellular Therapy, Director of Translational Research and Director of the GMP Facility at the MD Anderson Cancer Centre. Prof Rezvani’s research laboratory focuses on the role of natural killer (NK) cells in mediating immunity against haematologic and solid organ tumours. This research has led to the approval and funding of several investigator-initiated clinical trials of NK cell immunotherapy in patients with hematologic malignancies and solid tumors, as well as the first-in-human clinical trial of off-the-shelf CAR-transduced cord blood NK cells in patients with relapsed/refractory lymphoid malignancies. Prof Rezvani’s work is supported by multiple grants from the National Cancer Institute, the Leukemia and Lymphoma Society, the American Cancer Society, Stand Up to Cancer and the Cancer Prevention & Research Institute of Texas (CPRIT). In this webinar, Prof Rezvani will be outlining the emerging role of NK cell based therapeutics in cancer.
Professor Katy Rezvani – MD Anderson Cancer Centre
When: Friday 26 August 2022, 8am AEST
For full information click here
HSANZ is pleased to support the 2nd Sickle Cell Conference on 10 September 2022, a hybrid event with virtual facilities over zoom
Venue: 220 Pitt St Wesley Conference Centre, Wesley Theatre.
Time: 09:00 am to 6:00 pm
Follow this link to register:
Sickle Cell Warriors and Caregivers join us for free. Register via this link for free registration.
The blood cancer Optimal Care Pathways project is an initiative of the Blood Cancer Taskforce and was jointly led by the Australasian Leukaemia & Lymphoma Group (ALLG) and the Haematology Society of Australia and New Zealand (HSANZ), with support from the Leukaemia Foundation.
The Blood Cancer Taskforce was pleased to launch 6 new Optimal Care Pathways (OCPs) for blood cancer on 9 August
These OCPs will set national standards of care and treatment for blood cancer patients across Australia, no matter where they live, or access treatment.
This is a huge achievement in our collective work towards zero lives lost to blood cancer by 2035. Thank you to HSANZ Vice-President who was the Chair of this committee.
To view the OCPs, click on this link
© 2023 Haematology Society of Australia & New Zealand All Rights Reserved.